Compliance and reports
EHA is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research and education in hematology.
In pursuing this mission, EHA acts exclusively in the interest of hematology and its practitioners and is bound by core values of independence, integrity and transparency. To ensure these interests, EHA has several instruments in place.
The association’s independence is assured through its statutes which state that its members are individual scientific researchers or physicians who can demonstrate an active interest in the discipline of hematology. The members of EHA, assembled in the business meeting, are the sovereign authority of the association. They appoint the EHA governing body; the Board of Directors which manages the association. In turn, the Board is accountable for its policies and finances to the members at least once a year, at the business meeting.
Good Governance Committee
The EHA Good Governance Committee is established to propose policies and to provide advice – on request or voluntarily – to the EHA Board with the objective to negate or minimize the risk of (potential or perceived) conflict between the interest of EHA and other, e.g. commercial, interest. Many of the below policies have been the result of the work of this committee.
Members of the Board, the Committees and the staff of EHA are obliged to declare any conflict of interest (COI) that they may have. In addition, they are obliged, annually, to sign a declaration that lists any affiliations they have with industry that could potentially form a COI.
Congress and education
For all continuing medical education (CME), including EHA Annual Congress or online education, EHA applies for accreditation at the European Board for Accreditation in Hematology (EBAH). The Standards & Guidelines of EBAH-CME Accreditation ensures the independence of the organizer, the topic selection, the speaker selection, and the educational materials. In addition, these Standards & Guidelines prescribe a number of conditions that the educational event must meet, such as the obligation of faculty to disclose their industry affiliations with industry.
EHA has annexed to all corporate sponsor contracts the EBAH-CME Code of Conduct which effectively binds sponsors to a priori adherence to the EBAH-CME Standards & Guidelines.
In addition, EHA Board members and invited speakers at the EHA Congress are precluded from speaking at industry organized satellite symposia at EHA Congress.
EHA further assures educational quality and independence by having installed an autonomous working committee called the Review Board that ensures that all educational content is original, up-to-date, and relevant to users of the EHA Medical Education Program.
HemaSphere is the new open access journal of EHA. Over the next years, we aim to develop HemaSphere as one of the top hematology journals, publishing basic, translational and clinical research of very high level. At the same time, we aim to make HemaSphere also the premier hematology information resource. HemaSphere is not just another journal in the field of hematology: we will support basic research and clinical hematology by offering a fast and constructive review process, and we will provide news articles relevant for hematologists, researchers and policymakers. As the journal is brand new, this offers a great opportunity to publish your work in HemaSphere.
In addition to HemaSphere, EHA also promotes Haematologica as its second open access journal, providing even more options for publishing your research with open access and at an affordable cost. Haematologica follows the recommendations, including those that concern conflicts of interests, of the International Committee of Medical Journal Editors (ICMJE). The editor-in-chief of Haematologica enjoys full editorial freedom, which means he or she has full authority over the editorial content of their journal and the timing of publication of that content. The content of this Journal is peer reviewed and abides to very specific rules, including the obligation to disclose, with respect to the submission and publication of the manuscript.
EHA is a Public Benefit Organization (PBO) under Dutch Tax Law. This status obliges EHA to comply with a set of rules that include ensuring that more than ninety percent of our efforts are focused on the common good and publishing a yearly report on its activities and finances on the EHA website.
EHA is an evaluated and confirmed Healthcare professional organization eligible to be involved in European Medicines Agency . EHA must comply with stringent funding and governance requirements as stipulated in the Criteria to be fulfilled by healthcare professionals' organisations involved in EMA activities .
EHA is a member of the Alliance for Biomedical Research in Europe (BioMed Alliance). As a member, EHA is bound by the Code of Conduct for Healthcare Professionals and Scientific Organizations. This important document sets out core principles to maintain and enhance professional independence, objectivity and scientific integrity.
The annual report of the activities of the European Hematology Association in 2016 is available here
The annual report of the activities of the European Hematology Association in 2015 is available here
The annual report of the activities of the European Hematology Association in 2014 is available here.
The annual report of the activities of the European Hematology Association in 2013 is available here.
EHA aims for long-term relationships of mutual benefit with its sponsors . Apart from membership fees, registration fees, and charity sponsorship, sponsorship from industry is of great importance to fund EHA’s activities.
EHA is registered in the EU Transparency Register under identification number 91666778136-14.
Income EHA 2016:
Industry related income as % of overall income: 58.8 %
Of which, the highest contribution from a single company: 7.7 %
Non-industry related income as % of overall income: 41.2 %
The code of conduct/policy regulating EHA’s relationship with and independence from the sponsors is disclosed to the EMA.